Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and…
Shionogi Receives Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter, “Shionogi”) announced that it had…
Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among…
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Adults with Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer Ono Pharmaceutical Co., Ltd. today announced that Ono Pharma Taiwan Co., Ltd. (Taipei, Taiwan; “OPTW”), a Taiwanese subsidiary of Ono, received…
Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA® (valbenazine) Capsules Achieve Higher VMAT2 Target Occupancy Than AUSTEDO XR Neurocrine Biosciences, Inc. today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR…
BMS Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Teens with oHCM Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents…
Gordian Bio Enters Research Partnership with Pfizer to Drive Obesity Target Discovery Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to…
The appointment strengthens leadership of the company’s U.S. BioPharmaceuticals operations and strategic growth AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.Suarez will lead the execution of the Company’s previously…
Takeda and Protagonist File NDA for Rusfertide in Polycythemia Vera Takeda Pharmaceutical Company Limited and Protagonist Therapeutics, Inc. have announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational…
Bayer Regulatory milestones build on FDA’s recent accelerated approval for previously treated HER2-mutant lung cancer patients Bayer announced that regulatory authorities in both the United States and China have granted Breakthrough Therapy Designation to sevabertinib as a potential first-line treatment…
Finerenone Receives Approval in Japan for Chronic Heart Failure Treatment Bayer today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia™), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients with…
FDA Approves Subcutaneous Form of Roche’s Lunsumio VELO™ for Relapsed or Refractory Follicular Lymphoma Roche announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab), as a subcutaneous (SC) formulation, for the treatment…